+49 30 648 35 164 service@chameleon-pharma.com


View of Istambul from the see under the sunset

Featured image: Photo by Engin Yapici on Unsplash

The OTC and pharma market in Turkey

Turkey, land of the Seljuks and Ottomans, is a coun­try at the gate­way of mod­ern­isa­tion between Europe and Asia. Turkey has been a com­pet­i­tive coun­try since the beginning of civilisation—and as today’s Pharma indus­try gains momentum there, the coun­try promises qual­ity partnerships, rigorous challenges and, yes, even more competition.

Turkey has taken many steps towards a work­ing health­care sys­tem. The health­care sys­tem in Turkey has entered a long period of devel­op­ment under the 2003-2013 Health Trans­for­ma­tion Pro­gram. The pur­pose of the pro­gram is to increase the qual­ity and effi­ciency of the health­care sys­tem and enhance access to health­care facil­i­ties. Accord­ing to the Phar­ma­ceu­ti­cal Man­u­fac­tur­ers Asso­ci­a­tion of Turkey (IEIS), the Turk­ish phar­ma­ceu­ti­cal mar­ket was worth around US $11.6 bil­lion in 2012, up from US $4 bil­lion in 2003, grow­ing by a compound annual growth rate (CAGR) of 12.6%. Turkey has nearly 300 local phar­ma­ceu­ti­cal com­pa­nies and 49 man­u­fac­tur­ing com­pa­nies, with 13 of those belonging to for­eign investors. The indus­try employs approx­i­mately 25,000 peo­ple.


There are many OTC, Med­ical Device and Food Sup­ple­ment com­pa­nies sell­ing West­ern Euro­pean prod­ucts to huge suc­cess. The Turkish Gen­eral Direc­torate of Phar­ma­ceu­ti­cals and Phar­macy, a divi­sion of the Min­istry of Health, is in charge of reg­u­la­tion and con­trol of phar­ma­ceu­ti­cal prices. Man­u­fac­tur­ers and importers are obliged to apply to the Min­istry of Health for the autho­risa­tion of new prod­uct prices, as well as for price increases and decreases.

The most fre­quent causes of death in Turkey are, in order of fre­quency, can­cer, heart dis­ease and cerebral-vascular dis­eases. More than 80% of one-year olds received inoc­u­la­tions against child­hood dis­eases in 2004. Cur­rently, Turkey has a pop­u­la­tion of nearly 79 mil­lion, mean­ing it expe­ri­enced a total growth of 1.2% in the past year. In com­par­i­son to the coun­tries surrounding it, this is a rapidly increas­ing birth rate. It’s no stretch to say that Turkey is one of the lead­ing phar­ma­ceu­ti­cal mar­kets in the world, burst­ing at the seams with pos­si­bil­i­ties.

To help you work your way into this teem­ing mar­ket, we at CPC have devel­oped a sys­tem­atic part­ner search process to iden­tify your best-fit­ting part­ner in only 10–12 weeks.

The CPC approach will allow you to save time on the ‘get­ting-to-know-you’ meet­ings with pos­si­ble part­ners, as well as cut down on your travel costs and make you feel confident that you have the best part­ner for sales growth. To ana­lyse the Turk­ish mar­ket specif­i­cally, we use a SWOT analy­sis, which always offers many inter­est­ing out­comes. Despite its risks, the Turk­ish mar­ket is loaded with growth and poten­tial.

CPC Press Releases on Turkey:

Turkey – TRIUMPH country

Turkey in numbers

Total population


Population growth

Birth rate

Mortality rate

Life expectancy

Interested in this market?

We are ready to support you in Strategy, Marketing, Systematic International Company Partner Identification, Commercial Due Diligence, Business Development, Acquisition Search, Regulatory projects, and more in order to ensure your growth.